Novo Nordisk's CEO Lars Fruergaard Jørgensen is stepping down due to market challenges and a significant drop in share price. The company has faced increased competition from Eli Lilly and has revised its sales and profit growth forecasts downward. Jørgensen will remain in his position until a successor is found. Teljes cikk (Euronews.com)